ArticleDiabetes care2026
Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTeplizumab delays progression from stage 2 to stage 3 type 1 diabetes (T1D). Epstein-Barr virus (EBV) reactivation after teplizumab is usually transient and mild. We report EBV reactivation-associated secondary hemophagocytic lymphohistiocytosis (HLH) in an adult with trisomy 21 who was treated with teplizumab. RESEARCH DESIGN AND
methodsWe describe the clinical course, virologic testing, histopathology, treatment, and follow-up of a 44-year-old man with trisomy 21 and stage 2 T1D after a 14-day teplizumab course.
resultsSix days after completion of the 14-day teplizumab course, he developed respiratory, hepatic, and renal failure. EBV PCR peaked at >2,000,000 copies/mL; serology confirmed reactivation. Lymph node biopsy showed EBV-associated lymphoproliferation, and criteria for secondary HLH were fulfilled (HScore 238). Dexamethasone and four weekly rituximab doses were associated with clinical, biochemical, and virologic recovery. At 12 months, he remained clinically stable with stage 2 T1D and no insulin treatment.
conclusionsThis case documents EBV reactivation-associated secondary HLH after teplizumab treatment in a patient with trisomy 21. Causality cannot be established, and the absence of pretreatment EBV PCR limits assessment of whether preexisting EBV DNAemia at treatment initiation contributed to the poor outcome. The observation raises a plausible but unproven host-virus-drug interaction and supports early EBV PCR and HLH evaluation after severe inflammatory deterioration after teplizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.